117 related articles for article (PubMed ID: 1552096)
1. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension.
Schrader BJ; Inbar S; Kaufmann L; Vestal RE; Rich S
J Am Coll Cardiol; 1992 Apr; 19(5):1060-4. PubMed ID: 1552096
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of nifedipine, verapamil, and diltiazem on experimental pulmonary hypertension.
Young TE; Lundquist LJ; Chesler E; Weir EK
Am J Cardiol; 1983 Jan; 51(1):195-200. PubMed ID: 6571766
[TBL] [Abstract][Full Text] [Related]
3. Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension.
Inbar S; Schrader BJ; Kaufmann E; Vestal RE; Rich S
J Am Coll Cardiol; 1993 Feb; 21(2):413-8. PubMed ID: 8426006
[TBL] [Abstract][Full Text] [Related]
4. Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension.
Brownlee JR; Beekman RH; Rosenthal A
Pediatr Res; 1988 Aug; 24(2):186-90. PubMed ID: 3186330
[TBL] [Abstract][Full Text] [Related]
5. Effects of dopamine and nifedipine infusions on the pulmonary circulation of the lamb.
Feltes TF; Fike CD; Hansen TN
Pediatr Pharmacol (New York); 1986; 5(4):261-71. PubMed ID: 3737271
[TBL] [Abstract][Full Text] [Related]
6. Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease.
Alpert MA; Pressly TA; Mukerji V; Lambert CR; Mukerji B; Panayiotou H; Sharp GC
Am J Cardiol; 1991 Dec; 68(17):1687-91. PubMed ID: 1746473
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension.
Barst RJ
Chest; 1986 Apr; 89(4):497-503. PubMed ID: 2869919
[TBL] [Abstract][Full Text] [Related]
8. Adenosine as a vasodilator in primary pulmonary hypertension.
Morgan JM; McCormack DG; Griffiths MJ; Morgan CJ; Barnes PJ; Evans TW
Circulation; 1991 Sep; 84(3):1145-9. PubMed ID: 1884445
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic effects of nifedipine on secondary pulmonary hypertension in man.
Garzaniti N; el Allaf D; D'Orio V; Cremers S; Marcelle R; Carlier J
Acta Cardiol; 1985; 40(2):207-15. PubMed ID: 3873156
[TBL] [Abstract][Full Text] [Related]
10. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing.
Rich S; Kaufmann E
J Am Coll Cardiol; 1991 Nov; 18(5):1323-7. PubMed ID: 1918710
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic effects of nifedipine versus hydralazine in primary pulmonary hypertension.
Fisher J; Borer JS; Moses JW; Goldberg HL; Niarchos AP; Whitman HH; Mermelstein M
Am J Cardiol; 1984 Sep; 54(6):646-50. PubMed ID: 6475787
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of nifedipine in pulmonary hypertension.
Klugmann S; Salvi A; Fioretti P; Camerini F
G Ital Cardiol; 1982; 12(7):505-8. PubMed ID: 7169146
[TBL] [Abstract][Full Text] [Related]
13. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine.
Ricciardi MJ; Knight BP; Martinez FJ; Rubenfire M
J Am Coll Cardiol; 1998 Oct; 32(4):1068-73. PubMed ID: 9768734
[TBL] [Abstract][Full Text] [Related]
14. Hemodynamic effects of nifedipine in primary pulmonary hypertension.
Douglas JS
J Am Coll Cardiol; 1983 Jul; 2(1):174-9. PubMed ID: 6853910
[TBL] [Abstract][Full Text] [Related]
15. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension.
Nootens M; Schrader B; Kaufmann E; Vestal R; Long W; Rich S
Chest; 1995 Jan; 107(1):54-7. PubMed ID: 7813311
[TBL] [Abstract][Full Text] [Related]
16. Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension.
Brett SJ; Simon J; Gibbs R; Pepper JR; Evans TW
Thorax; 1996 Jan; 51(1):89-91. PubMed ID: 8658378
[TBL] [Abstract][Full Text] [Related]
17. Inhaled nitric oxide potentiates actions of adenosine but not of sodium nitroprusside in experimental pulmonary hypertension.
Patterson KW; Deb B; Kavanagh BP; Pearl RG
Pharmacology; 1999 May; 58(5):246-51. PubMed ID: 10087465
[TBL] [Abstract][Full Text] [Related]
18. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease.
Packer M; Medina N; Yushak M
J Am Coll Cardiol; 1984 Nov; 4(5):890-901. PubMed ID: 6491082
[TBL] [Abstract][Full Text] [Related]
19. Effect of infused adenosine on cardiac output and systemic resistance in normal subjects.
Bush A; Busst CM; Clarke B; Barnes PJ
Br J Clin Pharmacol; 1989 Feb; 27(2):165-71. PubMed ID: 2713212
[TBL] [Abstract][Full Text] [Related]
20. Nifedipine dilates the pulmonary vasculature without producing symptomatic systemic hypotension in upright resting and exercising patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease.
Muramoto A; Caldwell J; Albert RK; Lakshminarayan S; Butler J
Am Rev Respir Dis; 1985 Nov; 132(5):963-6. PubMed ID: 4062050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
